WuXi XDC Sets IPO Price at Top of End of Range
By P.R. Venkat
A unit of Chinese contract drugmaker Wuxi Biologics set its initial public offering price at the top end of its guided range, indicating strong demand in a choppy year for listings in Hong Kong.
The company said Wuxi XDC Cayman will raise 3.68 billion Hong Kong dollars, the equivalent of $470.9 million, after the final IPO price was set at HK$20.60 a share.
The company had marketed the shares at a price range of HK$19.90 to HK$20.60/share.
People familiar with the deal had said earlier that Wuxi XDC closed its order book early due to strong demand.
Shares of the company, which does research, development and manufacturing with a focus on antibody-drug conjugate, a type of medicine for cancer treatment, will start trading on the Hong Kong exchange Nov. 17.
The IPO secured commitments from some global investors, including Invesco, Qatar's sovereign wealth fund, and HongShan, the investment firm formerly known as Sequoia Capital China, according to Wuxi XDC's listing document.
Write to P.R. Venkat at venkat.pr@wsj.com
(END) Dow Jones Newswires
November 15, 2023 18:22 ET (23:22 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Q4 Stock Market Outlook: Where We See Opportunities for Investors
-
Markets Brief: Non-Farm Payrolls in the Spotlight Again
-
6 Top-Performing Large-Growth Funds
-
What’s the Difference Between the CPI and PCE Indexes?
-
This Cheap Stock Is Still a Buy Even After 50% Rally
-
10 Top-Performing Dividend Stocks of Q3 2024
-
33 Undervalued Stocks
-
Communication Services: Cable’s Broadband Dominance Isn’t as Strong as It Once Was
-
Technology: Strength Continues, With Software Presenting the Best Buying Opportunities
-
Best- and Worst-Performing Stocks of Q3 2024
-
Top Stocks to Own From the Best Fund Managers
-
2 Cheap Stocks Top Managers Have Been Buying